BIT.BIO
Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the... cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.
BIT.BIO
Industry:
Biotechnology Commercial Health Care
Founded:
2016-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.bit.bio
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
144.96 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Tag Manager Amazon Google Maps Cloudflare COVID-19 Cloudflare Network Error Logging Cloudflare SSL
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
HealthVerity
HealthVerity powers the discovery, licensing, and linkage of traditional and emerging healthcare data.
Current Advisors List
Current Employees Featured
Founder
Investors List
Resilience
Resilience investment in Series B - bit.bio
Metaplanet Holdings
Metaplanet Holdings investment in Series B - bit.bio
ArchVentures SA
ArchVentures SA investment in Series B - bit.bio
Tencent
Tencent investment in Series B - bit.bio
Puhua Capital
Puhua Capital investment in Series B - bit.bio
Charles River Laboratories International
Charles River Laboratories International investment in Series B - bit.bio
Milad Alucozai
Milad Alucozai investment in Series B - bit.bio
Foresite Capital
Foresite Capital investment in Series B - bit.bio
Rick Klausner
Rick Klausner investment in Series A - bit.bio
BlueYard Capital
BlueYard Capital investment in Series A - bit.bio
Official Site Inspections
http://www.bit.bio Semrush global rank: 1.54 M Semrush visits lastest month: 16.98 K
- Host name: 199.60.103.36
- IP address: 199.60.103.36
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
More informations about "bit.bio"
About us | bit.bio
What we do. bit.bio is a synthetic biology company providing human cells for research, drug discovery and cell therapy. The company applies a patented safe harbour gene-targeting …See details»
Join Our Team | Working at bit.bio | bit.bio
Bit.bio are committed to attracting, developing and retaining the highest quality employees. Vital to pursing this aim is the recognition of employees for exceptional performance, behaviour and …See details»
bit.bio - Crunchbase Company Profile & Funding
Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation …See details»
bit.bio Company Profile 2025: Valuation, Funding
When was bit.bio founded? bit.bio was founded in 2016. Where is bit.bio headquartered? bit.bio is headquartered in Cambridge, United Kingdom. What is the size of bit.bio? bit.bio has 200 total employees. What industry is bit.bio in? …See details»
Mark Kotter - Wikipedia
Kotter has made contributions to the importance of macrophages for brain regeneration, [2] His work on cell programming includes the development of opti-ox (optimized inducible …See details»
bit.bio - Funding, Financials, Valuation & Investors - Crunchbase
Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell.See details»
bit.bio - Contacts, Employees, Board Members, Advisors & Alumni
Organization. bit.bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 11. Number of Board …See details»
Bit Bio - Overview, News & Similar companies | ZoomInfo.com
Nov 1, 2023 Nobel Laureate Thomas Südhof and bit.bio CEO Mark Kotter to Lead Fireside Chat on Programming Human Cells at SynBioBeta CAMBRIDGE, England--(BUSINESS WIRE)-- …See details»
Life Sciences Directory: BIT BIO Discovery GmbH
Organization type RDM biotech/pharma Region Vienna Focus human health Profile. bit.bio discovery combines single cell functional genomics with best-in-class cellular models to …See details»
bit.bio expands Executive Team with appointment of Przemek …
Cambridge, UK, 08:00, 31 July 2024 – bit.bio, the company coding human cells for novel cures and a pioneer in the field of synthetic biology, today announces the appointment of Przemek …See details»
Who Owns bit.bio – CANVAS, SWOT, PESTEL & BCG Matrix …
Dec 19, 2024 [cbm_blg_rlnkng]Who Owns bit.bio: As the biotech industry continues to expand and innovate, one company that has caught the attention of many is bit.bio. Founded by a …See details»
Bit Bio Company Profile - Office Locations, Competitors ... - Craft
Bit Bio is a company that develops a cell reprogramming platform. Its platform provides human cell assays for research, disease-modeling, toxicology, and drug screening, allows the …See details»
Member profile: Bit Bio Ltd | BIA - BioIndustry
Founded in 2016 by Dr Mark Kotter, bit bio is an award-winning spinout from the University of Cambridge. By applying an engineering approach to synthetic and stem cell biology, Mark and …See details»
bit.bio - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Dec 15, 2024 The intellectual property of bit.bio includes 4 registered patents primarily in the ' Biochemistry; Beer; Spirits; Wine; Vinegar; Microbiology; Enzymology; Mutation Or Genetic …See details»
bit.bio - Cambridge&
Work started on what is now bit.bio’s opti-ox technology in 2012, in founder and CEO Mark Kotter’s research lab at Cambridge University. In 2017, his team showed that opti-ox works …See details»
Upcoming Events and Conferences | bit.bio
See the latest events and conferences that bit.bio is sponsoring, speaking or attending. Search. Cancel. Platform. Therapeutics. Therapeutics Cell therapies. Pipeline. Partnerships. ioCells. …See details»
bit.bio - Updates, News, Events, Signals & Triggers - Crunchbase
Bit.bio may be growing as it has recently unveiled a cell therapy candidate for liver conditions, indicating an expansion of its product pipeline. The company has also significantly expanded …See details»
News | bit.bio
Bit.bio's ioSensory Neurons pain research was selected for presentation at SfN’s Neuroscience 2024 press conference. 01.10.2024. Published by bit.bio. Read now. Press Release bit.bio …See details»
What is BIO Protocol and How to Buy $BIO Token? | Bitunix
1 day ago Tokenomics of BIO TOKEN: The token’s distribution and vesting schedule are meticulously designed to ensure sustainable growth and empower community-driven …See details»
Our platform for Reprogramming Cell Identity | Technology | bit.bio
At bit.bio we look at a cell as if it were a computer. The nucleus is the hard drive, storing genes in its DNA. Genes interact with one another, forming programs called gene regulatory networks. …See details»